TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04179773

Intervention type: OTHER
Intervention: Current care study
Description: Observational study in two parts:~1. Cross-sectional study of patients with digestive or ENT cancer with indication for conventional chemotherapy treatment according to management guidelines, the objective of which is to determine the frequency of cirrhosis.~2. Exposed/non-exposed cohort study of patients receiving a first course of conventional chemotherapy initiated in outpatient oncology clinic. (safety population).~Exposed subjects will be patients with cirrhosis, included consecutively. Non-exposed subjects will be non-cirrhotic patients. They will be selected non-consecutively according to the following criteria, for matching to exposed subjects: age (±5 years), type of cancer (digestive vs. ENT), treatment stage (curative vs. palliative). Two unexposed subjects will be selected for 1 exposed subject.

Intervention type: OTHER
Intervention: Current care study
Description: Observational study in two parts:~1. Cross-sectional study of patients with digestive or ENT cancer with indication for conventional chemotherapy treatment according to management guidelines, the objective of which is to determine the frequency of cirrhosis.~2. Exposed/non-exposed cohort study of patients receiving a first course of conventional chemotherapy initiated in outpatient oncology clinic. (safety population).~Exposed subjects will be patients with cirrhosis, included consecutively. Non-exposed subjects will be non-cirrhotic patients. They will be selected non-consecutively according to the following criteria, for matching to exposed subjects: age (±5 years), type of cancer (digestive vs. ENT), treatment stage (curative vs. palliative). Two unexposed subjects will be selected for 1 exposed subject.
Study: NCT04593810

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: INTELLiVENT-ASV
Description: INTELLiVENT-ASV is activated as soon possible. The sensors for ETCO2 and SpO2 are connected and activated. Patient's gender and height are set on the ventilator and patient condition is chosen if applicable.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: CONVENTIONAL VENTILATION
Description: Conventional ventilation consists of VCV or PCV and PSV, depending on patient's activity. None of the semi or fully automated modes of ventilation is allowed at any time.
Study: NCT03756181

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Five-week MSC program (MSC5wk)
Description: This program adaptation will consist of conducted meditative practices, discussions, and background information within a group setting of no more than 25 students per group. The facilitator may discuss the student's experience and encourage group sharing within the course of the session. These discussions will reinforce the guiding principles of mindfulness meditation. There will also be sessions dedicated to incorporating or mindfulness in daily life, with more detailed instructions, as well as encouraging a 30- minute daily home practice.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Five-week MSC program (MSC5wk)
Description: This program adaptation will consist of conducted meditative practices, discussions, and background information within a group setting of no more than 25 students per group. The facilitator may discuss the student's experience and encourage group sharing within the course of the session. These discussions will reinforce the guiding principles of mindfulness meditation. There will also be sessions dedicated to incorporating or mindfulness in daily life, with more detailed instructions, as well as encouraging a 30- minute daily home practice.
Study: NCT04530032

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: ketogenic/modified Atkins diet
Description: ketogenic/modified Atkins diet use

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Standard diet
Description: standard (normal) diet use
Study: NCT03339986

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Reduction or Replacement

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Reduction or Replacement
Study: NCT04506866

Intervention type: DEVICE
Group type: OTHER
Intervention: InterStim Micro
Description: Eligible subjects will receive InterStim Micro therapy. Commercial devices will be used within their intended use as described in each geography's approved instructions for use

Intervention type: DEVICE
Group type: OTHER
Intervention: InterStim Micro
Description: Eligible subjects will receive InterStim Micro therapy. Commercial devices will be used within their intended use as described in each geography's approved instructions for use

Intervention type: DEVICE
Group type: OTHER
Intervention: InterStim Micro
Description: Eligible subjects will receive InterStim Micro therapy. Commercial devices will be used within their intended use as described in each geography's approved instructions for use
Study: NCT01898338

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fosfomycin 2gr/6h iv

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fosfomycin 2gr/6h iv

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Daptomycin 10mg/kg/24h iv
Study: NCT01116570

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Physical training
Description: Physical training during 24 weeks

Intervention type: OTHER
Group type: OTHER
Intervention: Control
Description: No intervention
Study: NCT01412008

Intervention type: DRUG
Group type: NO_INTERVENTION
Intervention: Botox (botulinum toxin)
Description: A series of three injections will be made simultaneously to the gastroc-soleus muscles of the affected lower limb; this will be the only drug intervention/injection session throughout the study, and occurs at baseline. The top injection site, closest to the knee, consists of 25 units of Botox and 0.25 cc saline. The bottom injection site, closest to the ankle, also consists of 25 units of Botox and 0.25 cc saline. The middle injection site will be considered the placebo injection, as it will not contain any Botox (0 units Botox) and 0.25 cc saline.
Study: NCT03550313

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Multivalent
Description: Pneumococcal conjugate vaccine
Study: NCT03891433

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Meropenem
Description: Carbapenems group intervention.
Study: NCT02435537

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Morphine
Description: intrathecal 0.5mg morphine

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Morphine
Description: intrathecal 0.5mg morphine
Study: NCT05930054

Intervention type: DEVICE
Group type: OTHER
Intervention: skeletal anchorage and rapid palatal expansion
Description: Eighteen patients were randomly divided into 2 groups through a free randomization program (Random Allocation Software 2.0). Baseline demographic characteristics were matched in both groups. All appliances were fabricated by the same technician in the orthodontic lab. All individuals were treated by a single practitioner.

Intervention type: DEVICE
Group type: OTHER
Intervention: skeletal anchorage and rapid palatal expansion
Description: Eighteen patients were randomly divided into 2 groups through a free randomization program (Random Allocation Software 2.0). Baseline demographic characteristics were matched in both groups. All appliances were fabricated by the same technician in the orthodontic lab. All individuals were treated by a single practitioner.
Study: NCT00810667

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lu AE58054
Description: twice daily oral dose (60 mg BID: total dose 120 mg/day)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: twice daily oral dose
Study: NCT03578432

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Everolimus
Description: Given PO

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Survey Administration
Description: Ancillary studies
Study: NCT00204698

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Aciphex
Description: 20 mg of aciphex taken twice daily
Study: NCT01438892

Intervention type: DRUG
Intervention: tDMARDs
Description: Traditional DMARDs for RA

Intervention type: DRUG
Intervention: biodmards
Description: Biologic DMARDs
Study: NCT01610674

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Tailored improvement strategy
Description: A step-wise implementation model is applied:~1) recommendations on optimal perioperative diabetes care (e.g. the administration of intravenous insulin, encouragement of diabetes self-management) are systematically translated into quality indicators; 2a) using these quality indicators, current care is measured by performing a medical record search among 400 patients in 6 hospitals; 2b) barriers and facilitators for optimal care are measured by performing interviews with professionals 3) based on this information an implementation strategy is developed; 4) implementation activities are enacted in 3 hospitals and 5) evaluated in a controlled before-after design in 6 hospitals providing before and after intervention 400 patients.
Study: NCT02667704

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bosentan

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nintedanib
Study: NCT03891433

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ertapenem 1000 MG
Description: Carbapenems group intervention.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Piperacillin, Tazobactam 4-0.5G Solution for Injection
Description: Piperacillin/Tazobactam group intervention.
Study: NCT01851122

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: L-theanine capsule
Description: L-theanine 250mg capsule

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo capsule
Study: NCT02176655

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: VVD-101
Description: All subjects will treat 6 headaches with either VVD-101 or placebo in a randomized order.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: All subjects will treat 6 headaches with either VVD-101 or placebo in a randomized order.
Study: NCT05009693

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: White Light Application
Description: White Light Therapy
Study: NCT04201574

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ALY688 0.1%
Description: ALY688 0.1% Ophthalmic Solution

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ALY688 0.4%
Description: ALY688 0.4% Ophthalmic Solution

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Vehicle
Description: Vehicle Ophthalmic Solution
Study: NCT00669097

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TKI258
Study: NCT01316003

Intervention type: OTHER
Intervention: Optical coherence tomography
Description: Optical coherence tomography
Study: NCT01708382

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Ulthera System Treatment
Description: Focused ultrasound energy delivered below the surface of the skin
Study: NCT04620447

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Intelligent Virtual Reality Therapy System (IVRTS)
Description: The approach of the Novel Intelligent Software interface approaches follows the basic premise that human beings think in terms of images rather than words. While the existing modes of treatment for phobias rely mainly on talk therapies and counseling; This novel intelligent software treatment methodology deals with the development of VR programs integrated with hardware for simulating various phobia-inducing situations, followed by novel automated integrated most effective psychotherapy; altering these images to reduce the anxiety experienced. Our treatment package includes a VR device integrated with easily comprehensible voice commands, along with a user manual and easy user interface, thereby reducing the effort of training required for operating the device. The framework is a combination of the therapy methodologies with VR, motion sensors and biofeedback.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Intelligent Virtual Reality Therapy System (IVRTS)
Description: The approach of the Novel Intelligent Software interface approaches follows the basic premise that human beings think in terms of images rather than words. While the existing modes of treatment for phobias rely mainly on talk therapies and counseling; This novel intelligent software treatment methodology deals with the development of VR programs integrated with hardware for simulating various phobia-inducing situations, followed by novel automated integrated most effective psychotherapy; altering these images to reduce the anxiety experienced. Our treatment package includes a VR device integrated with easily comprehensible voice commands, along with a user manual and easy user interface, thereby reducing the effort of training required for operating the device. The framework is a combination of the therapy methodologies with VR, motion sensors and biofeedback.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Intelligent Virtual Reality Therapy System (IVRTS)
Description: The approach of the Novel Intelligent Software interface approaches follows the basic premise that human beings think in terms of images rather than words. While the existing modes of treatment for phobias rely mainly on talk therapies and counseling; This novel intelligent software treatment methodology deals with the development of VR programs integrated with hardware for simulating various phobia-inducing situations, followed by novel automated integrated most effective psychotherapy; altering these images to reduce the anxiety experienced. Our treatment package includes a VR device integrated with easily comprehensible voice commands, along with a user manual and easy user interface, thereby reducing the effort of training required for operating the device. The framework is a combination of the therapy methodologies with VR, motion sensors and biofeedback.
Study: NCT00751920

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Enhanced MRI Scan
Description: Following the detection of a pulmonary nodule(s) with the unenhanced MRI scan, the subjects will then be injected with the contrast agent, Magnevist, and have a dynamic enhanced MRI scan of the largest pulmonary nodule.
Study: NCT02089373

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Probe-based confocal laser endomicroscopy
Description: In this arm1, an investigator observes a cancerous lesion using white light endoscopy. In addition, contrast dye for confocal laser endomicorscopy (fluorescein sodium 0.1mL/kg) is administered. Then, the cancerous lesion is observed using probe-based confocal laser endomicroscopy. The biopsy would be done 5 times at the most suspcious parts of the cancerous lesion.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: White light endoscopy
Description: In this arm2, an invesigator observes a cancerous lesion using white light endoscopy. The biopsy would be done 5 times at the most suspicious parts of the cancerous lesion.
Study: NCT00516022

Intervention type: DRUG
Group type: OTHER
Intervention: Mistletoe extract
Description: The drug will be administered 3 times a week at home.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mistletoe extract
Description: The drug will be administered 3 times a week at home.
Study: NCT05056207

Intervention type: OTHER
Group type: OTHER
Intervention: Cohort I (patients receiving annual lymphedema screening
Description: patientns who previously underwent preoperative perometer lymphedema screening

Intervention type: OTHER
Group type: OTHER
Intervention: Cohort II (patients followed intensively for lymphedema)
Description: patients who have recently undergone ALND
Study: NCT00604591

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Tolcapone
Description: 200 mg by mouth three times a day

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tolcapone
Description: 200 mg by mouth three times a day

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 200 mg by mouth three times a day

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: 200 mg by mouth three times a day
Study: NCT05079542

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Timepoint of Implant placement of Bonelevel tapered implants
Description: Implant surgery on different time points

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Timepoint of Implant placement of Bonelevel tapered implants
Description: Implant surgery on different time points

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Material for tooth restoration - Lithiumdisilicate glass ceramic or zirconia
Description: Tooth restoration with a certain material

Intervention type: COMBINATION_PRODUCT
Group type: ACTIVE_COMPARATOR
Intervention: Material for tooth restoration - Lithiumdisilicate glass ceramic or zirconia
Description: Tooth restoration with a certain material
Study: NCT00298272

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: IDEC-C2B8 (rituximab)
Description: Participants will receive 500 mg rituximab on Day 1 and Day 15

Intervention type: DRUG
Group type: OTHER
Intervention: Placebo
Description: Participants will receive placebo on Day 1 and Day 15

Intervention type: DRUG
Group type: OTHER
Intervention: Methotrexate
Description: Participants must have been treated with MTX ≥15 mg per week and ≤25 mg per week (dose may have been as low as 10 mg if unable to tolerate higher dose) for at least 12 weeks immediately prior to Day 1, at a stable dose for at least 4 weeks and was continued for the study duration.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methotrexate
Description: Participants must have been treated with MTX ≥15 mg per week and ≤25 mg per week (dose may have been as low as 10 mg if unable to tolerate higher dose) for at least 12 weeks immediately prior to Day 1, at a stable dose for at least 4 weeks and was continued for the study duration.

Intervention type: DRUG
Group type: OTHER
Intervention: Etanercept
Description: Participants must have been treated with etanercept at 50 mg per week (25 mg twice per week or 50 mg once per week).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etanercept
Description: Participants must have been treated with etanercept at 50 mg per week (25 mg twice per week or 50 mg once per week).

Intervention type: DRUG
Group type: OTHER
Intervention: Adalimumab
Description: Participants must have been treated with adalimumab at 40 mg every other week for at least 12 weeks immediately prior to Day 1.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Adalimumab
Description: Participants must have been treated with adalimumab at 40 mg every other week for at least 12 weeks immediately prior to Day 1.

Intervention type: DRUG
Group type: OTHER
Intervention: Methylprednisolone
Description: Methylprednisolone 100 mg IV was administered by slow infusion to be completed at least 30 minutes prior to each infusion of rituximab or placebo.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methylprednisolone
Description: Methylprednisolone 100 mg IV was administered by slow infusion to be completed at least 30 minutes prior to each infusion of rituximab or placebo.

Intervention type: DIETARY_SUPPLEMENT
Group type: OTHER
Intervention: Folate
Description: All subjects also received a stable dose of folate (≥5 mg per week).

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Folate
Description: All subjects also received a stable dose of folate (≥5 mg per week).
Study: NCT01216241

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Daptomycin
Description: 8 MG/KG IV

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Saline Placebo
Description: 50 ml normal saline once daily

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Daptomycin
Description: 8 mg/kg once daily
Study: NCT01075165

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: silicone spray
Description: application of silicone spray to predefined area qd 12 weeks

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: saline spray
Description: application of saline spray to predefined area qd 12 weeks
Study: NCT01209520

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: Patients will receive a total of 4 cycles of adjuvant chemotherapy (each cycle given every 21 days). Conventional chemotherapy will be selected at discretion of the treating physicians except on those cases in which pathologic diagnosis indicates non squamous NSCLC.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: Patients will receive a total of 4 cycles of adjuvant chemotherapy (each cycle given every 21 days). Conventional chemotherapy will be selected at discretion of the treating physicians except on those cases in which pathologic diagnosis indicates non squamous NSCLC.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: Patients will receive a total of 4 cycles of adjuvant chemotherapy (each cycle given every 21 days). Conventional chemotherapy will be selected at discretion of the treating physicians except on those cases in which pathologic diagnosis indicates non squamous NSCLC.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vidaza
Description: Patient will receive 5-azacitidine at a dose of 75 mg/m2 intravenously daily on day 1-5 every 28 days for 6 cycles

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Tumor Specimen for Methylation Analysis
Description: Obtained from tissue of resected NSCLC tumor.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Blood Sample for Methylation Analysis
Description: Pre-Surgery, Post-Surgery, Post-Vidaza Therapy and during follow-up.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vinorelbine
Description: Patients will receive a total of 4 cycles of adjuvant chemotherapy (each cycle given every 21 days). Conventional chemotherapy will be selected at discretion of the treating physicians except on those cases in which pathologic diagnosis indicates non squamous NSCLC.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel
Description: Patients will receive a total of 4 cycles of adjuvant chemotherapy (each cycle given every 21 days). Conventional chemotherapy will be selected at discretion of the treating physicians except on those cases in which pathologic diagnosis indicates non squamous NSCLC.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pemetrexed
Description: Patients will receive a total of 4 cycles of adjuvant chemotherapy (each cycle given every 21 days). Conventional chemotherapy will be selected at discretion of the treating physicians except on those cases in which pathologic diagnosis indicates non squamous NSCLC.